Accelerated platelet activation in Asian Indians with diabetes and coronary artery disease - The Chennai Urban Population Study (CUPS-13)

Journal of Association of Physicians of India

Volumn 54, Issue SEP., 2006, Pages 704-708

  Deepa, R ^a   Mohan, V ^a   Premanand, C ^a   Rajan, V S ^a   Karkuzhali, K ^a   Velmurugan, K ^a   Agarwal, S ^a   Gross, M D ^b   Markovitz, J ^c  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ASIAN; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; INDIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICS; THROMBOCYTE ACTIVATION; URBAN POPULATION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; INDIA; MIDDLE AGED; PLATELET ACTIVATION; URBAN POPULATION;

EID: 33748570791     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. McKeigue PM, Ferrie JE, Pierpoint T, Marmot MG. Association of early-onset coronary heart disease in South Asian men with glucose intolerance and hyperinsulinemia. Circulation 1993;87:152-61.
2. Hughes K, Yeo PPB, Lun KC et al. Ischaemic heart disease and its risk factors in Singapore in comparison with other countries. Ann Acad Med 1989;18:245-9.
3. Mohan V, Sharp PS, Cloke HR, Burrin JM, Schemer B, Kohner EM. Serum immunoreactive insulin responses to a glucose load in Asian Indian and European Type 2 (non-insulin dependent) diabetic patients and control subjects. Diabetologia 1986;29:235-7.
4. Mather HM and Keen H. The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans. BMJ 1985;291:1081-4.
5. Markovitz JH, Kulkarni K, Goldschmidt-Clermont P et al. Increased platelet activation and fibrinogen in Asian Indians. Potential implications for coronary risk. Eur Heart J 1998;19:720-6.
6. Rauch U, Ziegler D, Piolot R, et al. Platelet activation in diabetic cardiovascular autonomic neuropathy. Diabet Med 1999;16:848-52.
7. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24:1476- 85.
8. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-8.
9. Chandalia M, Abate N, Garg A, Stray-Gundersen J, Grundy SM. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:2329-35.
10. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596-601.
11. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
12. Shanthirani CS, Rema M, Deepa R, et al. The Chennai Urban Population Study (CUPS) - Methodological details (CUPS Paper No.1). Int J Diab Dev Countries 1999;19:149-57.
13. Alberti KG, Zimmet PZ. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO Consultation. Diabet Med 1998;15:539-53.
14. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
16. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9.
17. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992;41:26-31.
18. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome -The Chennai Urban Rural Epidemiology Study. Metabolism 2006;55:237-42.
19. The IMPACT-II investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-8.
20. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O'connor CM. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003;146:713-20.
21. Peters RJ, Mehta SR, Fox KA, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7.
22. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.